Dermatology News and Research

Latest Dermatology News and Research

‘Real-world’ ambrisentan data unveiled

The use of and outcomes with ambrisentan in clinical practice are different to those in clinical trials, reflecting different patient characteristics in the “real world”, say researchers.

11 Jun 2014

Haemodynamic exercise variables “important” for PAH prognostication

Exercise haemodynamic variables, measured shortly after diagnosis, correlate with exercise capacity and predict survival in patients with pulmonary arterial hypertension, study findings indicate.

11 Jun 2014

ClarityMD effective in clearing acne without irritation

Envy Medical, Inc., a leader in professional skincare products and services, is excited to announce the publication of a new study in the June issue of the Journal of Drugs in Dermatology (JDD) proving the superior efficacy of its highly innovative acne system – ClarityMD.

11 Jun 2014

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.

9 Jun 2014

Prevalence of pulmonary arterial hypertension characterised in CHD patients

Pulmonary arterial hypertension affects just over 3% of individuals with congenital heart disease, reveal nationwide data from the Netherlands.

6 Jun 2014

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers.

6 Jun 2014

Blood pressure has heterogeneous associations with cardiovascular diseases

The associations between blood pressure and cardiovascular disease are variable, reveals a large study that highlights the impact of angina and heart failure.

5 Jun 2014

High CHD risk in diabetic women confirmed

A meta-analysis confirms that the excess risk for coronary heart disease in patients with diabetes is greater in women than men.

5 Jun 2014

Four new genes cause inherited breast cancer risk

Four new genes have been added to the growing list of those known to cause increased breast cancer risk when mutated through the efforts of researchers at Huntsman Cancer Institute (HCI) at the University of Utah, who lead an international consortium working to find more gene mutations that cause inherited breast cancer susceptibilities.

5 Jun 2014

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

4 Jun 2014

Region Skåne and Sectra sign six-year agreement

Region Skåne, one of Sweden's largest care providers, has signed a six-year agreement with IT and medical technology company Sectra.

4 Jun 2014

Pivotal clinical validation study of Myriad myPath Melanoma test presented at ASCO 2014

Myriad Genetics, Inc. today presented results from a pivotal clinical validation study of the Myriad myPath- Melanoma test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Ill.

2 Jun 2014

Valeant, Pershing Square make revised proposal to acquire all outstanding shares of Allergan

Allergan, Inc. ("Allergan" or the "Company") today acknowledged that Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the "Re-Revised Proposal").

31 May 2014

Actavis signs deal with Cephalon to settle patent litigation related to Nuvigil tablets

Actavis plc today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil® (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg).

31 May 2014

Perelman School wins $10M renewal to study oldest part of human immune system

The National Institute of Allergy and Infectious Diseases has awarded the Perelman School of Medicine at the University of Pennsylvania a five-year, $10 million renewal of a program project to study the oldest part of the human immune system called the complement system, or simply "complement."

30 May 2014

Rare type of melanoma that attacks palms, soles twice likely to recur, says NYU study

A rare type of melanoma that disproportionately attacks the palms and soles and under the nails of Asians, African-Americans, and Hispanics, who all generally have darker skins, and is not caused by sun exposure, is almost twice as likely to recur than other similar types of skin cancer, according to results of a study in 244 patients.

30 May 2014

Noninvasive laser therapy triggers stem cells to repair enamel of teeth

A Harvard-led team is the first to demonstrate the ability to use low-power light to trigger stem cells inside the body to regenerate tissue, an advance they reported in Science Translational Medicine.

29 May 2014

JNC 8 blood pressure target for elderly queried

The systolic blood pressure of elderly people should be kept below 140 mmHg, say researchers who dispute the eighth Joint National Committee guidelines.

28 May 2014

WHO member states recognize psoriasis as chronic, non-communicable disease

At the 67th World Health Assembly, the WHO member states adopted a resolution on psoriasis, recognizing it as "a chronic, non-communicable, painful, disfiguring, and disabling disease for which there is no cure."

27 May 2014

World Health Assembly approves resolution on viral hepatitis and noncommunicable diseases

The World Health Assembly approved a resolution to improve the prevention, diagnosis and treatment of viral hepatitis and proposals to improve global coordination of efforts to address noncommunicable diseases like diabetes, cancers, heart disease and stroke. In addition, WHO's Director-General and the President of the Health Assembly presented 4 awards to leaders in public health.

23 May 2014